

## QIBA FDG-PET/CT Tech Ctte Update Call

April 13, 2012 at 9 am CT

Call Summary

### In attendance:

Paul Kinahan, PhD (co-chair)

Richard Wahl, MD (co-chair)

Keith Allberg

Andrew Buckler, MS

Paul E. Christian

Barbara Croft, MD

Howard Higley, PhD

Larry R. MacDonald, PhD

Eric S. Perlman, MD

Ling X. Shao, PhD

Anne M. Smith, PhD

Rathan Subramaniam, MD

Daniel C. Sullivan, MD

Valerie Treyer, PhD

John G. Wolodzko, PhD

Jeffrey T. Yap, PhD

Brian E. Zimmerman, PhD

### RSNA

Joe Koudelik

Julie Lisiecki

### Discussion regarding the Profile updates (Dr. Kinahan)

- Dr. Kinahan reviewed the updated version 06.1.1 of the Profile working document
- Acronyms section must still be populated
- Precise definition for SUV still needed
- Normative definitions also require some additional parameters
- An Executive Summary was added with updated diagram showing the Profile claim
- References are still needed for key statements, i.e., detection of malignant tumors
- Additional information regarding regulatory enforcement is needed
- Adding references for QIBA/ MITA position papers with expectations / guidelines for vendors suggested
- Vendor (i.e., actor) responsibilities need to be extremely clear within the Profile
- Common DICOM standards/ fields need to be implemented across vendor products
- Dr. Shao suggested creating a standard template/ spreadsheet for patient prep
  - Possible attachment to the Profile - would incorporate height, weight, software version, QA, etc.

### New sections added

- Part IV – Compliance (technical specifications are new)
- Applications and Endpoints (must be updated for consistency)

### More discussion needed

- Strength of the “carrot” under discussion to encourage QIBA compliance
- Consideration of a third-party broker for assessment of compliance
- QIBA compliance is positioned to be world-wide
- These items are currently under consideration by the QIBA Steering Committee
- Two articles were published in *Radiology* on collaboration and regulatory issues; however, it is always good to consider additional ways to spread the word regarding the value of the Profile

### Next steps:

- Dr. Kinahan to incorporate edits from 4/13 call and circulate to the group for review prior to the next call
- Continue discussion of final Profile edits on next call prior to release for Public Comment
- Dr. Kinahan to add references and analysis as an appendix
- Dr. Kinahan to clarify some of the terms in the abbreviations and acronyms sections: SUV, SUVmax, etc.

**Next call:** [to continue discussion of the Profile at 9 am \(CT\), April 20<sup>th</sup>](#)